Dostarlimab shows promise in advanced recurrent microsatellite instability-high mismatch repair deficiency endometrial cancer in PI GARNET study

Patients given 500mg of dostarlimab once every three weeks for four doses, followed by 1000mg once every six weeks (until disease progression) showed an objective response rate of 42% and a disease control rate of 58%.

SPS commentary:

In April 2020, the European Medicines Agency accepted a marketing authorisation application for dostarlimab (a humanised anti-programmed death-1 monoclonal antibody) for this indication.